Brain scan biomarkers may predict who benefits from epilepsy heat treatment
NCT ID NCT07399327
First seen Mar 05, 2026 · Last updated Jun 22, 2026 · Updated 19 times
Summary
This study will follow 45 people with drug-resistant focal epilepsy who are already scheduled for a brain procedure called SEEG-guided thermocoagulation. Researchers will use MRI scans, brain recordings, and blood tests before and after treatment to find markers that predict whether the procedure stops seizures. The goal is to better understand why some patients respond well and others do not, which could lead to more personalized treatment decisions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DRUG RESISTANT EPILEPSY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SEEG-guided radiofrequency thermocoagulation (RFTC)
What this could lead to
If successful, this could help doctors better select which brain targets to treat with thermocoagulation, improving seizure control for people with drug-resistant epilepsy.
What could go wrong
This is an early-stage observational study with only 45 participants, so results may not apply widely. The treatment itself has variable success rates, and the study focuses on understanding mechanisms rather than proving a new therapy works.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.